a compilation of articles on novel medicines put together by the WHO EURO secretariat as part of the Novel Medicines Platform (NMP), an initiative that HAI has been accompanying since its inception (under the Oslo Medicine Initiative ) with discussions on operating principles and procedures of the nascent European Access Dialogue Platform (EADP) scheduled for first week of December
Hope you find it useful
https://www.bmj.com/collections/novel-medicines
This collection features the recently published BMJ articles related to our ongoing collaboration and highlights key insights from the Oslo Medicines Initiative and the Novel Medicines Platform.
Editorial
Equitable access to costly new drugs
Pricing should consider local value to ensure fair access and health system affordability, write Beth Woods, Renske ten Ham, and Karl Claxton
Analysis
Managing costly new drugs to support equitable access: international collaboration and patient engagement to assess value, and managed entry agreements
Tarang Sharma and colleagues argue for increased collaboration across public and private sectors—internationally and with patients—in drug assessment and managed entry agreements to support equitable and sustainable access to costly medicines
Pharmaceutical governance system for costly drugs through human rights due diligence
The obligations and responsibilities of governments and drug companies to increase access to costly new drugs should be grounded in international human rights, write Trudo Lemmens and colleagues
Collective international action to increase access to costly drugs: pooled procurement and equity based tiered pricing
Zoltán Kaló and colleagues consider approaches to counter systemic inequities and power imbalances arising from discrete national policies for drug pricing and reimbursement
Policy actions to promote affordability and access across the lifecycle of costly new drugs
Strategic collaboration among countries and sectors on policies that prioritise equity throughout the full medicine life cycle could make innovative therapies more affordable and accessible globally, argue Krista Kruja and colleagues
We encourage you to explore the articles and share this link with your networks as appropriate.
Kind regards,
The Novel Medicines Platform Secretariat
WHO/Europe Access to Novel Medicines Platform
